Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of XmAb23104 in People With Sarcoma

ClinicalTrials.gov ID: NCT05879185

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05879185. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 2:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of XmAb23104 (Targeting PD-1 and ICOS), in Patients With Advanced Sarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out whether the study drug, XmAb23104, is an effective treatment for advanced sarcoma. The researchers will also look at whether XmAb23104 is safe and causes few or mild side effects in participants.

Study identification

NCT ID
NCT05879185
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Enrollment
6 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 6, 2023 (Actual)
Primary completion
Jul 19, 2024 (Actual)
Completion
Jul 19, 2024 (Actual)
Last update posted
Apr 13, 2026

2023 – 2024

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey 07920 —
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 —
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 —
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) Commack New York 11725 —
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 —
Memorial Sloan Kettering Cancer Center New York New York 10065 —
Memorial Sloan Kettering Nassau (Limited Protocol Activities) Rockville Centre New York 11553 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05879185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 13, 2026 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.